New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
Enanta Pharmaceuticals (NASDAQ:ENTA) announced new preclinical data for EDP-235, its oral coronavirus protease inhibitor aimed at treating COVID-19, to be presented at IDWeek 2022 from October 19-23, 2022, in Washington, DC. An oral presentation is scheduled for October 21, 2022, at 12:15 PM ET, discussing EDP-235's potential to mitigate cytokine storms in high-risk COVID-19 patients. Enanta continues its focus on small molecule drugs for viral infections and liver diseases, supported by royalties from its collaboration with AbbVie on hepatitis C virus products.
- Presentation of promising preclinical data for EDP-235 at IDWeek 2022.
- Potential of EDP-235 to mitigate cytokine storms in high-risk COVID-19 patients.
- Ongoing funding from royalties related to hepatitis C treatments.
- None.
Oral Presentation
Date:
Time: 12:15 –
Session Title: Rapid Fire Poster Session: COVID-19 Clinical Issues
Session Location:
Presentation Title: “EDP-235, A Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes, with the Potential for Mitigation of Cytokine Storm in High-Risk COVID-19 Patients”
Presenter:
Poster Presentation
Date:
Time: 12:15 –
Session Title: COVID-19: Treatment
Session Location:
Poster #1123: “EDP-235, A Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes, with the Potential for Mitigation of Cytokine Storm in High-Risk COVID-19 Patients”
Presenter:
Posters will be available to view on the conference platform during the conference. Further information about IDWeek 2022 can be found here.
About
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005418/en/
Media and Investors
617-744-3848
jviera@enanta.com
Source:
FAQ
What is EDP-235 and its purpose?
When will the new preclinical data for EDP-235 be presented?
Where will the IDWeek 2022 conference be held?
What are the implications of EDP-235's data presentation for the market?